By David Sachs
Merck KGaA said that it has partnered with BenevolentAI and Exscientia on an initiative to discover more drugs with artificial intelligence, which the company says will yield higher success rates.
The German science and technology company said on Wednesday that the partnership with the two U.K. AI firms includes access to an AI platform to generate new drug candidates in oncology, cancer, neurology and immunology. BenevolentAI and Exscientia will each receive upfront payments for their work in the low double-digit millions and will be eligible for additional payments depending on net sales.
The deal includes three potential drug targets with the possibility of more in the future, Merck said. Financial details were not disclosed.
Write to David Sachs at email@example.com